A phase III, randomized, open-label study evaluating the efficacy and safety of Giredestrant in Combination with phesgo versus phesgo after induction Therapy with Phesgo+taxane in patients with previously untreated her2-positive, estrogen receptor-positive locally-advanced or metastatic breast cance

Condition: Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Sponsor: Genetech_Roche

Phase: 3

A phase III, randomized, open-label study evaluating the efficacy and safety of Giredestrant in Combination with phesgo versus phesgo after induction Therapy with Phesgo+taxane in patients with previously untreated her2-positive, estrogen receptor-positive locally-advanced or metastatic breast cancer